Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis

Keyphrases

• Meta-analysis 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Chemotherapy Agents 100%
• Third Generation 100%
• Platinum-based 100%
• Risk Difference 85%
• Confidence Interval 71%
• Monotherapy 71%
• 1-year Survival 42%
• Non-small Cell Lung Cancer (NSCLC) 28%
• Best Supportive Care 28%
• Inclusion Criteria 14%
• Randomized Trial 14%
• Gemcitabine 14%
• Randomized Controlled Trial 14%
• Am(III) 14%
• Tumor Response 14%
• Paclitaxel 14%
• Exclusion Criteria 14%
• Irinotecan 14%
• MEDLINE 14%
• Tumor Survival 14%
• Subset Analysis 14%
• Docetaxel 14%
• High Response Rate 14%
• Risk Response 14%
• Equivalency 14%
• Platinum Doublets 14%
• Vinorelbine 14%
• Three-arm Trial 14%

Medicine and Dentistry

• Meta-Analysis 100%
• Non Small Cell Lung Cancer 100%
• Attributable Risk 100%
• Chemotherapy Agent 100%
• Monotherapy 83%
• Survival Rate 33%
• Supportive Care 33%
• Neoplasm 16%
• Arm 16%
• Randomized Controlled Trial 16%
• Paclitaxel 16%
• Irinotecan 16%
• Gemcitabine 16%
• Docetaxel 16%
• Treatment of Non-Small Cell Lung Cancer 16%
• Vinorelbine 16%